SciClone Hit With Shareholder Suit Amid DOJ, SEC Probe
SciClone Pharmaceuticals Inc., already the target of U.S. Department of Justice and Securities and Exchange Commission investigations, now faces a class action for allegedly making false and misleading statements to inflate...To view the full article, register now.
Already a subscriber? Click here to view full article